Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
03.10.23
/
50%
€27.40
Target price
03.10.24
€65.04
Performance (%)
-32.12%
Price
25.07.24
€18.40
Summary
This prediction is currently active. Massive losses of -32.12% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 03.10.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 2.222% | 2.222% |
iShares Core DAX® | 1.280% | 1.320% |
iShares Nasdaq 100 | -2.457% | -5.192% |
iShares Nikkei 225® | -2.006% | -1.389% |
iShares S&P 500 | -0.662% | -1.884% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
01.03.24
01.03.24
€41.56
01.03.25
01.03.25
-29.01%
25.07.24
25.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.40
03.11.23
03.11.23
€54.04
03.11.24
03.11.24
-36.97%
25.07.24
25.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€34.80
03.08.23
03.08.23
€62.07
03.08.24
03.08.24
-47.13%
25.07.24
25.07.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24